ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Potential Allergenicity of New Wheat Varieties

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02341040
Recruitment Status : Terminated (insufficient subjects recruited in allotted time)
First Posted : January 19, 2015
Last Update Posted : May 21, 2018
Sponsor:
Collaborator:
Monsanto Company, LLC
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The goal of the study is to determine accurate blood test levels that can predict whether or not subjects are truly allergic to certain foods. In this study, subjects that are clinically documented to be wheat-allergic will participate in a double blind oral food challenge. Blood will be collected from the subject to evaluate the potential allergenicity of proteins introduced into genetically modified crops and evaluate wheat-specific immunoglobulin-e (IgE) antibody reactivity to biotech and conventional wheat varieties.

Condition or disease
Food Allergy Wheat Allergy

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 5 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Potential Allergenicity of New Wheat Varieties
Study Start Date : November 2014
Actual Primary Completion Date : May 15, 2018
Actual Study Completion Date : May 15, 2018

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Determine the relationship between whole wheat-specific IgE and IgE to components [ Time Frame: ~2 weeks ]
    Logistic regression analyses will be performed to establish diagnostic decision pointsindicating a high likelihood of symptomatic food allergy to wheat, thus potentiallypreventing unnecessary food challenges for patients with wheat allergy..


Secondary Outcome Measures :
  1. Determine the relationship between IgE components and oral food challenge [ Time Frame: ~2 weeks ]
    The investigators will evaluate IgE to components Tri a 14, Tri a 19, and Tri a Aa_TI, and Oral Food Challenges outcomes.

  2. Determine the Cross-Reactivity between wheat and grass allergens [ Time Frame: ~1 month ]
    To assess cross-reactivity between wheat and grass allergens in wheat-allergic patients.

  3. Determine the Potential Allergenicity [ Time Frame: ~1 month ]
    To evaluate the potential allergenicity of putative wheat allergens.

  4. Establish a Serum Repository [ Time Frame: ~2 weeks ]
    To establish a serum repository at Monsanto of wheat-reactive allergic patients.


Biospecimen Retention:   Samples Without DNA
Subjects may opt to have extra blood drawn. This sample will be de-identified and sent to the sponsor, Monsanto, for future study that is yet to be determined.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Pediatric and adult subjects between the ages of 1 (inclusive) to 21 years (inclusive) that have sensitivity to wheat
Criteria

Inclusion Criteria:

  • Age 1 year to 21 years of any sex and any race
  • Physician-diagnosed food allergy to wheat with convincing clinical history of food allergy to wheat AND a skin prick test positive to wheat (diameter of wheal 3 mm or greater than negative control) or a detectable serum food-specific IgE level (ImmunoCAP > 0.35 kUA/L) to wheat within the previous 12 months or at the time of entry into the study
  • If no history of clinical reactivity to wheat, then a positive skin prick test to wheat (diameter of wheal 3 mm or greater than negative control) OR a detectable serum food-specific IgE level to wheat within the previous 12 months or at the time of entry into the study
  • Patients who meet any of the following criteria are eligible for enrollment as study participants if they meet all other criteria, but will not undergo a DBPCFC:

    • Recent (within one year) failed open OFC
    • Positive DBPCFC to wheat at CHCO
    • Recent (within one year) exposure to wheat resulting in immediate IgE-mediated allergic symptoms (within 2 hours of ingestion; symptoms such as urticaria, angioedema, congestion, rhinorrhea, wheezing, respiratory compromise, hypoxia, hypotension)
  • Written informed consent from parent/guardian and assent (when age appropriate).
  • Willingness to submit specimen for laboratory serum IgE testing
  • Willingness to submit lab specimen for ELISA testing

Exclusion Criteria:

  • Inability to discontinue antihistamines for skin prick testing and OFCs
  • FEV1 value <80% predicted OR any clinical features of moderate or severe persistent asthma, as defined by the 2007 NHLBI guidelines table for classifying asthma, at the time of entry into the study
  • Use of >500 μg/day fluticasone or equivalent
  • Asthma requiring either:

    • 1 hospitalization in the past year for asthma, or
    • 1 ER visit in the past 6 months for asthma
  • Use of steroid medications (IV, IM or oral) for asthma in the following manners:

    • history of daily oral steroid dosing for >1 month during the past year, or
    • steroid course/burst in the past 3 months (except for steroid dosing used in the treatment of an allergic reaction during the DBPCFC), or
    • 2 steroid courses/bursts in the past year.
  • History of intubation due to allergies or asthma
  • Diagnosis of active eosinophilic gastrointestinal disease in the past year
  • Severe atopic dermatitis, as assessed by a Three-Item Severity Score of 6 or greater

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02341040


Locations
United States, Colorado
Children's Hospital Colorado
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Monsanto Company, LLC
Investigators
Principal Investigator: David Fleischer, MD University of Colorado, Denver

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT02341040     History of Changes
Other Study ID Numbers: 14-1416
UL1TR001082 ( U.S. NIH Grant/Contract )
First Posted: January 19, 2015    Key Record Dates
Last Update Posted: May 21, 2018
Last Verified: May 2018

Keywords provided by University of Colorado, Denver:
wheat allergy
food allergy
pediatric

Additional relevant MeSH terms:
Hypersensitivity
Food Hypersensitivity
Wheat Hypersensitivity
Immune System Diseases
Hypersensitivity, Immediate